Table of Contents Author Guidelines Submit a Manuscript
Erratum

An erratum for this article has been published. To view the erratum, please click here.

Disease Markers
Volume 2014, Article ID 671283, 3 pages
http://dx.doi.org/10.1155/2014/671283
Research Article

Molecular Targeted Approaches for Advanced BRAF V600, N-RAS, c-KIT, and GNAQ Melanomas

1Department of Clinical and Diagnostic Medicine and Public Health, University of Modena and Reggio Emilia, Via del Pozzo 71, 41100 Modena, Italy
2Department of Dermatology, University of Modena and Reggio Emilia, Via del Pozzo 71, 41100 Modena, Italy
3Department of Plastic and Reconstructive Surgery, University of Modena and Reggio Emilia, Via del Pozzo 71, 41100 Modena, Italy
4Department of Medical Oncology, University of Modena and Reggio Emilia, Via del Pozzo 71, 41100 Modena, Italy
5Dermatology & Skin Cancer Unit, Arcispedale Santa Maria Nuova, IRCCS, Reggio Emilia, Italy

Received 10 June 2013; Revised 19 November 2013; Accepted 19 November 2013; Published 23 January 2014

Academic Editor: Dinesh Kumbhare

Copyright © 2014 Ponti Giovanni et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. A. Ascierto, J. M. Kirkwood, J.-J. Grob et al., “The role of BRAF V600 mutation in melanoma,” Journal of Translational Medicine, vol. 10, article 85, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Y. Morita and S. N. Markovic, “Molecular targets in melanoma: time for ‘ethnic personalization’,” Expert Review of Anticancer Therapy, vol. 12, no. 5, pp. 601–608, 2012. View at Google Scholar
  3. H. Davies, G. R. Bignell, C. Cox et al., “Mutations of the BRAF gene in human cancer,” Nature, vol. 417, no. 6892, pp. 949–954, 2002. View at Publisher · View at Google Scholar
  4. J. L. Maldonado, J. Fridlyand, H. Patel et al., “Determinants of BRAF mutations in primary melanomas,” Journal of the National Cancer Institute, vol. 95, no. 24, pp. 1878–1890, 2003. View at Publisher · View at Google Scholar
  5. J. A. Curtin, J. Fridlyand, T. Kageshita et al., “Distinct sets of genetic alterations in melanoma,” The New England Journal of Medicine, vol. 353, no. 20, pp. 2135–2147, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Ponti, G. Pellacani, A. Tomasi et al., “The somatic affairs of BRAF: tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations,” Journal of Clinical Pathology, vol. 66, no. 5, pp. 441–445, 2013. View at Google Scholar
  7. G. Ponti, A. Tomasi, and G. Pellacani, “Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E, V600M) metastatic malignant melanoma,” Journal of Hematology & Oncology, vol. 5, article 60, 2012. View at Google Scholar
  8. J. A. Curtin, K. Busam, D. Pinkel, and B. C. Bastian, “Somatic activation of KIT in distinct subtypes of melanoma,” Journal of Clinical Oncology, vol. 24, no. 26, pp. 4340–4346, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Ambrosini, C. A. Pratilas, L. X. Qin et al., “Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance,” Clinical Cancer Research, vol. 18, no. 13, pp. 3552–3561, 2012. View at Google Scholar
  10. G. Ambrosini, E. Musi, A. L. Ho, E. de Stanchina, and G. K. Schwartz, “Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death,” Molecular Cancer Therapeutics, vol. 12, no. 5, pp. 768–776, 2013. View at Google Scholar
  11. S. Abu-Abed, N. Pennell, T. Petrella, F. Wright, A. Seth, and W. Hanna, “KIT gene mutations and patterns of protein expression in mucosal and acral melanoma,” Journal of Cutaneous Medicine and Surgery, vol. 16, no. 2, pp. 135–142, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Shi, X. Kong, A. Ribas, and R. S. Lo, “Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells toV600EB-RAF inhibition,” Cancer Research, vol. 71, no. 15, pp. 5067–5074, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Nazarian, H. Shi, Q. Wang et al., “Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation,” Nature, vol. 468, no. 7326, pp. 973–977, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. C. M. Johannessen, J. S. Boehm, S. Y. Kim et al., “COT drives resistance to RAF inhibition through MAP kinase pathway reactivation,” Nature, vol. 468, no. 7326, pp. 968–972, 2010. View at Publisher · View at Google Scholar · View at Scopus